The Laboratory AntiPlatelet Efficacy and Clinical Outcome Registry (LAPCOR)

Faculty Hospital Kralovske Vinohrady

Status: Completed

Conditions: Platelet Aggregation Onhibitors

Treatments: Drug: antiplatelet drugs - P2Y12 antagonists

Study type: Observational

Funder types: Other

Identifiers

NCT02264912

05-2008

Details and patient eligibility

About

The ongoing LAPCOR (Laboratory AntiPlatelet efficacy and Clinical Outcome Registry) registry was initiated in 2008 at a tertiary care cardiac center, and consecutive patients, who underwent intracoronary stent implantation, have been included regardless of whether percutaneous coronary intervention (PCI) was performed on urgent or elective basis.Patients were included in the registry after having signed an informed consent for participation. No exclusion criterion has been applied for the registry participation. Efficacy of P2Y12 receptor antagonists has been measured by quantitative flow cytometric analysis of vasodilator-stimulated phosphoprotein (VASP) phosphorylation according to the manufacturer protocol (Platelet VASP; Diagnostica Stago, Biocytex, Asnières, France) on a FACScan flow cytometer (Becton Dickinson). Occurrence of major adverse cardiac events at 30 days, 6-months and one year follow up has been investigated.

Enrollment: 2,016 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients after stent PCI treated with P2Y12 antagonist
• Written informed consent

Exclusion criteria

• None

Trial design

2,016 participants in 1 patient group

stent-PCI patients

Description:

Consecutive patients, who underwent intracoronary stent implantation, have been included regardless of whether percutaneous coronary intervention (PCI) was performed on urgent or elective basis.

Treatment:

Drug: antiplatelet drugs - P2Y12 antagonists